两例在使用lecanemab治疗阿尔茨海默病后出现的淀粉样蛋白相关影像异常（ARIA）病例及文献综述
Two cases of Amyloid-Related Imaging Abnormalities (ARIA) following lecanemab treatment for alzheimer's disease and a literature review.
作者信息
Wang Yingte, Yu Qun, Chen Bin, Zhou Jing, Li Zhiming, Liao Wang, Liu Jun, Yang Airong
机构信息
Department of Radiology, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510245, China.
Department of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510260, China.
出版信息
BMC Neurol. 2025 Jul 7;25(1):281. doi: 10.1186/s12883-025-04302-5.
OBJECTIVE
To investigate the imaging characteristics and management strategies of amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease (AD) patients treated with lecanemab.
METHODS
We report two clinical cases of ARIA following lecanemab treatment and analyze the imaging features, risk factors, and management strategies of ARIA based on the latest literature.
RESULTS
The occurrence of ARIA is associated with risk factors such as advanced age, ApoE ε4 carrier status, cerebral amyloid angiopathy (CAA), and a history of cerebrovascular disease.
CONCLUSION
During lecanemab treatment for AD, it is essential to fully understand the mechanisms, imaging characteristics, and management strategies of ARIA. Close monitoring of clinical symptoms and imaging changes is crucial for the timely detection and appropriate management of ARIA.
目的
探讨接受lecanemab治疗的阿尔茨海默病（AD）患者淀粉样蛋白相关影像异常（ARIA）的影像学特征及管理策略。
方法
我们报告了两例lecanemab治疗后发生ARIA的临床病例，并根据最新文献分析ARIA的影像特征、危险因素及管理策略。
结果
ARIA的发生与高龄、ApoE ε4携带者状态、脑淀粉样血管病（CAA）和脑血管疾病史等危险因素相关。
结论
在AD患者接受lecanemab治疗期间，充分了解ARIA的机制、影像学特征及管理策略至关重要。密切监测临床症状和影像变化对于ARIA的及时发现和恰当管理至关重要。
Zotero 插件